In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
News-Medical.Net on MSN
Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.
Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants published by Wiley online in CANCER, investigators found ...
Zacks Investment Research on MSN
JNJ gets EU nod for expanded use of Akeega in prostate cancer
J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results